Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Can-Fite BioPharma Ltd. (CANF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Can-Fite files an annual report on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical programs, financial results, capital structure, and corporate actions. These filings are sourced in real time from the SEC’s EDGAR system and are organized for convenient review.
In its Form 6-K reports, Can-Fite often furnishes press releases covering developments such as clinical trial enrollment updates for Namodenoson in hepatocellular carcinoma, MASH, and pancreatic cancer; Phase III progress for Piclidenoson in psoriasis; and new data from compassionate use programs in advanced liver disease. Filings also document regulatory designations like Orphan Drug and Fast Track status, patent grants and notices of allowance, and information about veterinary and human licensing agreements.
CANF’s SEC reports additionally address corporate and financing matters, including public offerings, warrant amendments, reverse stock splits, ADS ratio changes, and shareholder meeting outcomes. Financial statements presented under U.S. GAAP outline revenues from licensing and distribution agreements, research and development expenses for its A3 adenosine receptor-targeted pipeline, and general and administrative costs.
On this page, users can review individual filings and use AI-powered summaries to quickly understand the key points of lengthy documents such as the Form 20-F and detailed Form 6-K exhibits. The platform also makes it easier to track how specific clinical, regulatory, and capital markets events are reflected across multiple filings over time.
Can-Fite BioPharma Ltd. (CANF) submitted a Form 6-K to furnish a new press release about its liver cancer drug candidate Namodenoson. The filing states that the first paragraph of the press release is incorporated by reference into several existing Form S-8 and Form F-3 registration statements, meaning that key descriptive information about the company and its programs is now formally part of those documents. The press release, titled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson,” highlights an advanced liver cancer patient who achieved 9-year survival with a complete cure while being treated with Namodenoson. The Form 6-K itself does not provide additional clinical data or financial details beyond announcing and cross-referencing this communication.
Can-Fite BioPharma Ltd. reported that shareholders approved both proposals presented at its Special General Meeting on November 10, 2025. The proposals were described in the company’s Notice and Proxy Statement dated October 3, 2025, which was furnished as Exhibit 99.1 to a prior Form 6-K on October 3, 2025.
Can-Fite BioPharma Ltd. adjourned its Special General Meeting of Shareholders due to lack of quorum and will reconvene on Monday, November 10, 2025 at 3:00 p.m. (Israel time) at the company’s offices, 26 Ben Gurion Street, Ramat Gan, Israel.
Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders. The report is dated October 3, 2025 and is signed by Motti Farbstein, who is listed as Chief Executive Officer and Chief Financial Officer. The filing incorporates prior registration statements by reference to the extent not superseded.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.
The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.
Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer to provide investors with its operating and financial review and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The company also issued a press release on that date summarizing its financial results for the period and giving updates on its drug development programs. The 6-K specifies that the financial review, interim financial statements, and portions of the press release are incorporated by reference into several existing Form S-8 and Form F-3 registration statements, allowing those registration statements to use the newly furnished information.
Can-Fite BioPharma (CANF) has filed a Rule 424(b)(4) prospectus for a best-efforts capital raise. The company will sell up to 1.25 million American Depositary Shares (ADSs) at $0.60 each (1 ADS=300 ordinary shares) bundled with 2.5 million two-year Common Warrants exercisable at $0.60. Investors that would exceed 4.99%/9.99% ownership can instead buy up to 7.083 million Pre-Funded Warrants at $0.599, each exercisable for one ADS at $0.001. The filing also registers 583,333 Placement Agent Warrants (exercise price $0.75) and up to 24.33 million ADSs issuable upon warrant exercise.
Gross proceeds could reach $4.99 million; after 7% placement fee, 1% management fee and ~$246k expenses, net proceeds are estimated at $4.19 million. Funds will support R&D, clinical trials and general corporate purposes at management’s discretion.
Capital impact: outstanding ordinary shares rise from 3.997 billion (13.323 million ADSs) to 4.372 billion (14.573 million ADSs), a ~9% increase, or ~63% if all Pre-Funded Warrants are exercised immediately (total 8.333 million new ADSs). The warrants’ two-year term and low exercise price cap potential upside for existing holders and add future dilution.
CANF’s ADSs closed at $1.02 on 22 Jul 2025, a 70% premium to the $0.60 offer price, suggesting short-term pricing pressure. The deal includes 90-day lock-ups for the company and insiders and a one-year prohibition on variable-rate financings (subject to waiver).
Can-Fite BioPharma (CANF) disclosed a $5.0 million best-efforts public offering of equity and warrants. The July 28, 2025 deal comprises (i) 1.25 million ADSs (each equal to 300 ordinary shares) and (ii) 7.08 million pre-funded warrants plus 16.67 million common warrants, all priced at a combined $0.60 per ADS/ warrant unit ($0.599 for pre-funded units). Net proceeds after fees are expected to be $4.19 million.
The pre-funded warrants are immediately exercisable at $0.001 per ADS with no expiry; common warrants carry a $0.60 strike and two-year tenor. Exercisability is capped at 4.99% (optionally 9.99%) beneficial ownership. A single investor executed a definitive Securities Purchase Agreement that imposes a 90-day standstill and prohibits “variable-rate” financings for one year.
H.C. Wainwright acted as exclusive placement agent, earning 7% cash commission, 1% management fee, fixed expenses (~$165k) and agent warrants covering 7% of ADSs/pre-funded warrants, exercisable at $0.75.
Funds will support additional working capital, R&D and clinical trials. The offering, registered on Form F-1 (File No. 333-288890) declared effective July 28 2025, is expected to close on or about July 29 2025, subject to customary conditions.